Please login to the form below

Not currently logged in
Email:
Password:

Mallinckrodt

This page shows the latest Mallinckrodt news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt pays $1.2bn for Sucampo Pharma. The Irish group will acquire Amitizia, Rescula and a pipeline of rare disease projects. ... As 2017 drew to a close, Mallinckrodt signed a deal to buy Sucampo Pharma of the US - and its constipation drug

Latest news

  • Ireland's Mallinckrodt buys US regenerative medicine firm Ireland's Mallinckrodt buys US regenerative medicine firm

    Ireland's Mallinckrodt buys US regenerative medicine firm. Stratatech’ s StrataGraft in phase III testing for burns treatment. ... Ireland's Mallinckrodt Pharma has continued its acquisitive streak with a deal to buy Stratatech, a US firm developing a

  • Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase

    Ireland’ s Mallinckrodt makes $1.3bn immunotherapy purchase. Will acquire Therakos to further boost its hospital drug portfolio. ... This is Mallinckrodt's second major acquisition this year designed to bolster its presence in hospitals.

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    The muted response suggests some shareholders were hoping for a large-scale transformative deal - Mylan and Mallinckrodt had both been mentioned in dispatches as rumours of an a deal gathered last

  • Mallinckrodt cuts $5.6bn deal to buy Questcor Mallinckrodt cuts $5.6bn deal to buy Questcor

    Mallinckrodt cuts $5.6bn deal to buy Questcor. Irish company continues move from medical imaging to pharma products. ... Mallinckrodt has dug deep into its pockets to buy Questcor Pharma and gain ownership of its fast-growing specialty drug HP Acthar Gel.

  • Mallinckrodt offers $1.3bn for Cadence Pharma

    Mallinckrodt offers $1.3bn for Cadence Pharma. Deal would include injectable painkiller Ofirmev. ... Irish pharma company Mallinckrodt has agreed a $1.3bn deal to buy US biotech Cadence Pharmaceuticals and its fast-growing injectable painkiller Ofirmev.

More from news
Approximately 6 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Patent settlement, non-exclusive licence. 200. Mallinckrodt/Baxter International. RECOTHROM® Thrombin topical and PREVELEAK® Surgical Sealant to control bleeding in surgery.

  • Pharma deals continue to slide Pharma deals continue to slide

    products. While this may not have been the reason behind GSK’s termination of its rare disease projects, it has not deterred Mallinckrodt from acquiring Infacare, a US company with a ... 469 (upfront 31). Infacare (US). Mallinckrodt (US/GB). Company

  • Deal Watch August 2016 Deal Watch August 2016

    Mallinckrodt (US) Nuclear Imaging business. IBA Molecular (BE). Asset acquisition. Diagnostic imaging products for use in nuclear medicine including molybdenum-99.

  • Pharma deals in August 2015 Pharma deals in August 2015

    30600. Therakos. Mallinckrodt. Approved cell therapy platform for the palliative treatment of cutaneous T‐ cell lymphoma [CTCL].

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    3, 500. Ikaria / Mallinckrodt. Company acquisition. Marketed critical care treatments incl.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics